This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly's (LLY) Diabetes Drug Gets FDA Fast Track Tag for Obesity
by Zacks Equity Research
Eli Lilly (LLY) receives a fast-track designation from the FDA for tirzepatide to treat obesity in adult patients. The company will begin rolling NDA submission later this year.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $321.55, moving -0.56% from the previous trading session.
Will Acquisitions Help Novo Nordisk (NVO) Combat Stiff Rivalry?
by Zacks Equity Research
Novo Nordisk (NVO) expects new acquisitions to diversify its portfolio of marketed drugs and help combat the stiff competition in the diabetes market.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data
by Ekta Bagri
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.
Biogen's (BIIB) Lecanemab Meets Goal in Alzheimer's Study
by Zacks Equity Research
Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo.
AZN vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
AZN vs. LLY: Which Stock Is the Better Value Option?
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $307.50, moving -1.27% from the previous trading session.
Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK
by Kinjel Shah
Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.
Strength Seen in Lilly (LLY): Can Its 4.9% Jump Turn into More Strength?
by Zacks Equity Research
Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Eli Lilly (LLY) Gets FDA Nod for RET Inhibitor in Solid Tumors
by Zacks Equity Research
The FDA grants approval to Lilly's (LLY) Retevmo in advanced or metastatic solid tumors with a RET gene fusion. It converts the drug's accelerated approval in NSCLC indication to full approval.
AstraZeneca (AZN) Gets EU Nod for Evusheld to Treat COVID
by Zacks Equity Research
Following the label expansion approval in the European Union, Evusheld is currently the only long-acting antibody combination available for both prevention and treatment of COVID-19.
Eli Lilly (LLY) Stock Moves -1.1%: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $301.73 in the latest trading session, marking a -1.1% move from the prior day.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $309.61 in the latest trading session, marking a +1.02% move from the prior day.
Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug
by Zacks Equity Research
Syros Pharmaceuticals (SYRS) receives Orphan Drug designation from the FDA for its pipeline candidate AY-5609 being developed for treating metastatic pancreatic cancer. Stock up.
The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo, International Business Machines, Booking Holdings, Northrop Grumman Corporation and Illinois Tool Works
by Zacks Equity Research
Eli Lilly, PepsiCo, International Business Machines, Booking Holdings, Northrop Grumman Corporation and Illinois Tool Works are included in this Analyst Blog.
Top Stock Reports for Eli Lilly, PepsiCo & IBM
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), PepsiCo, Inc. (PEP) and International Business Machines Corporation (IBM).
How Investors Can Grab Better Returns for Medical Using the Zacks ESP Screener
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Pfizer (PFE) Alopecia Drug Filings Get Accepted by FDA, EMA
by Zacks Equity Research
FDA accepts Pfizer's (PFE) NDA for ritlecitinib for treating severe alopecia areata. The EMA also accepts the MAA for a similar patient population.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $311.60, marking a +1.56% move from the previous day.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $306.82, marking a +1.82% move from the previous day.
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $301.23 in the latest trading session, marking a -1.89% move from the prior day.
Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead?
by Zacks Equity Research
Lilly (LLY) expects to launch five new medicines by 2023-end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.
Foghorn (FHTX) Phase I AML/MDS Study on Full Clinical Hold
by Zacks Equity Research
Foghorn (FHTX) receives yet another setback as the phase I dose escalation study of FHD-286 in relapsed and/or refractory AML and MDS has been put on full clinical hold.